Effects of MaquiBright® on improving eye dryness and fatigue in humans: A randomized, double-blind, placebo-controlled trial

Abstract This study aims to investigate the effects of MaquiBright ® , also known as BrightSight ® , a standardized maqui berry extract, on improving eye dryness and fatigue in Japanese subjects (aged 30–60 years) experiencing eye dryness, eye fatigue, and ≥4 h of visual display terminal (VDT) work daily. Seventy-four participants were equally but randomly assigned to either a MaquiBright ® (MB) or a placebo (P) group, wherein each participant consumed one capsule daily for 4 weeks of the appropriate treatment (MaquiBright ® 60 or 0 mg). Eye dryness and fatigue were measured using the Schirmer's test, tear break-up time (BUT) test, pupillary response, and flicker test before intake and 4 weeks after intake. Furthermore, subjective symptoms were assessed using the Visual Analogue Scale (VAS) method and the Dry Eye–related Quality of Life Score (DEQS) questionnaire. The MB group demonstrated a significantly higher lacrimal fluid production in both eyes (increased 6.4 ± 8.1 mm, P  = 0.005) in Schirmer's test compared to the P group before VDT load (playing a video game) at 4 weeks after intake. In the VAS method after VDT load, the reduction of subjective symptoms in eye fatigue ( P  = 0.047) and stiff shoulders ( P  = 0.035) were significantly higher in the MB group than in the P group as well as bothersome ocular symptoms ( P  = 0.037) by the DEQS. No adverse events were reported. Thus, the consumption of 60 mg of MaquiBright ® per day for 4 weeks reduced eye dryness and seemed to alleviate eye fatigue.